Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis
- 8 September 1994
- journal article
- clinical trial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 331 (10), 637-642
- https://doi.org/10.1056/nejm199409083311003
Abstract
Respiratory disease in patients with cystic fibrosis is characterized by airway obstruction caused by the accumulation of thick, purulent secretions, which results in recurrent, symptomatic exacerbations. The viscoelasticity of the secretions can be reduced in vitro by recombinant human deoxyribonuclease I (rhDNase), a bioengineered copy of the human enzyme.Keywords
This publication has 19 references indexed in Scilit:
- Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosisThe Lancet, 1993
- The changing epidemiology of cystic fibrosisThe Journal of Pediatrics, 1993
- Cystic fibrosis: molecular biology and therapeutic implicationsScience, 1992
- Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 studyJAMA, 1992
- A Pilot Study of Aerosolized Amiloride for the Treatment of Lung Disease in Cystic FibrosisThe New England Journal of Medicine, 1990
- Validation of a Vertical Visual Analogue Scale as a Measure of Clinical DyspneaRehabilitation Nursing Journal, 1989
- Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosisThe Journal of Pediatrics, 1988
- Identifying costs of medical care. An essential step in allocating resourcesJAMA, 1985
- The rheological problem in chronic bronchitisRheologica Acta, 1958
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958